▶ TESOFENSINE · SUBTOPIC · DOSING LITERATURE

TESOFENSINE Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of TESOFENSINE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for TESOFENSINE reports the following route(s) of administration: Oral (clinical trial). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of TESOFENSINE.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for TESOFENSINE of approximately ~9 days. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of TESOFENSINE. Refer to the original publication for full protocol detail.

Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM (2008) reports the TESOFENSINE protocol used in Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial, published in Lancet. PMID 18950853. See the source for the protocol-level dose range, frequency, and duration. link
Bello NT, Zahner MR (2009) reports the TESOFENSINE protocol used in Tesofensine: A novel weight-loss agent for obesity treatment, published in Drug Discov Today Ther Strateg. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What is the half-life of tesofensine?

Approximately 9 days. Long half-life enables once-daily dosing with steady-state plasma levels after 4-5 weeks of treatment.

▶ What were the cardiovascular signals?

TIPO-1 reported dose-dependent increases in heart rate (~7 bpm at 1.0 mg) and modest blood pressure increases. The signal is manageable in further development but limits the dose ceiling and excludes patients with significant cardiovascular disease.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · Room temperature (capsule)

Reconstituted · n/a

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Saniona Phase 3 obesity programs ongoing.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ TESOFENSINE OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25